Misra Vijay P, Trosch Richard M, Maisonobe Pascal, Om Savary
1Imperial College Healthcare NHS Trust, London, UK.
4Peripheral Nerve Unit, Hammersmith Hospital, London, W12 0HS UK.
J Clin Mov Disord. 2018 Jul 9;5:4. doi: 10.1186/s40734-018-0072-8. eCollection 2018.
Cervical dystonia is a heterogeneous disorder with several possible presentations, for which first-line therapy is often botulinum toxin (BoNT). In routine clinical practice the success of each BoNT injection is dependent on several variables, including individual presentation and injection technique. Large multicenter, observational studies provide important information on individualized administration strategies that cannot be otherwise ascertained from controlled clinical trials. In this meta-analysis of patient level data, we aimed to evaluate the clinical characteristics of patients with cervical dystonia undergoing routine treatment with botulinum toxin, specifically abobotulinumtoxinA. We also aimed to characterize current abobotulinumtoxinA injection techniques and parameters and to explore international differences in patient presentation and treatment.
This was a meta-analysis of baseline data from three prospective, international, multicenter, observational studies (NCT01314365, NCT00833196 and NCT01753349) of botulinum toxin treatment for the routine management of adult cervical dystonia.
Data presented illustrate the significant heterogeneity of CD presentation in routine practice. Most subjects presented with a complex pattern of dystonic movements and the majority had additional components of shoulder elevation, tremor and/or jerk. Dosing was generally in accordance with that recommended in the abobotulinumtoxinA prescribing information, although the range of dosing also indicates that injections are tailored to individual presentation. Sub-group analyses at the country level revealed distinct differences in injection practice.
This meta-analysis is based on the largest dataset of subjects with cervical dystonia studied to date. The heterogeneity revealed in our baseline findings support the need to develop consistent, practical and comprehensive best practice guidelines.
颈部肌张力障碍是一种具有多种可能表现形式的异质性疾病,其一线治疗方法通常是肉毒毒素(BoNT)。在常规临床实践中,每次肉毒毒素注射的成功与否取决于多个变量,包括个体表现和注射技术。大型多中心观察性研究提供了关于个体化给药策略的重要信息,而这些信息无法从对照临床试验中获得。在这项对患者层面数据的荟萃分析中,我们旨在评估接受肉毒毒素(特别是a型肉毒毒素)常规治疗的颈部肌张力障碍患者的临床特征。我们还旨在描述当前a型肉毒毒素的注射技术和参数,并探讨患者表现和治疗方面的国际差异。
这是一项对三项前瞻性、国际性、多中心观察性研究(NCT01314365、NCT00833196和NCT01753349)的基线数据进行的荟萃分析,这些研究涉及肉毒毒素治疗成人颈部肌张力障碍的常规管理。
所呈现的数据表明,在常规实践中颈部肌张力障碍的表现存在显著异质性。大多数受试者表现出复杂的肌张力障碍运动模式,且大多数人伴有肩部抬高、震颤和/或抽搐等其他症状。给药通常符合a型肉毒毒素处方信息中的推荐剂量,尽管剂量范围也表明注射是根据个体表现进行调整的。国家层面的亚组分析显示了注射实践中的明显差异。
这项荟萃分析基于迄今为止研究的颈部肌张力障碍患者的最大数据集。我们基线研究结果中显示的异质性支持了制定一致、实用和全面的最佳实践指南的必要性。